Polycentric 384-month study of biofiltration (BF) with AN69s

Area of Science:

• Nephrology
• Biomedical Engineering

Background:

• Uremic patients often present with complex clinical signs requiring optimized dialysis strategies.
• Traditional hemodialysis may not fully address severe acidosis and cardiovascular instability.
• Biofiltration (BF) offers a potential alternative for managing these challenging patient profiles.

Purpose of the Study:

• To evaluate the clinical utility and effectiveness of biofiltration (BF) with AN69s in uremic patients.
• To assess the impact of BF on intradialytic complications and overall patient stability.
• To determine if BF can improve acid-base status and reduce dialysis-related morbidities.

Main Methods:

• A polycentric, randomized prospective study involving 39 uremic patients undergoing dialysis.
• Inclusion criteria focused on patients with poorly controlled clinical signs like severe acidosis and cardiovascular instability.
• Data collected over 384.15 total observation months (average 9.85 months/patient).

Main Results:

• Significant reduction in intradialytic hypotension incidence (26.6%).
• Decreased interdialytic body weight gain (3.1 to 2.7 kg, p<0.05).
• Reduced weekly dialysis time (12.3 to 10.0 hours, p<0.01) and improved acid-base status (ABS).

Conclusions:

• Biofiltration (BF) with AN69s demonstrates significant clinical utility in managing uremic patients.
• BF is particularly beneficial for patients experiencing severe acidosis and/or cardiovascular instability.
• The study supports BF as an effective strategy to improve dialysis efficiency and patient outcomes.